“I lie down and immediately feel the urge to urinate—multiple times each night, disrupting my sleep entirely.” This is a common yet underrecognized complaint among middle-aged and older men. Nocturia—defined as waking two or more times per night to void—is far more than an inconvenient side effect of aging. It’s often the earliest clinical sign of benign prostatic hyperplasia (BPH), and when left unaddressed, it contributes significantly to chronic sleep fragmentation, daytime fatigue, reduced cognitive performance, and diminished quality of life.
BPH is one of the most prevalent urological conditions in aging men. Epidemiological data indicate that approximately 40–50% of men over age 50 have histological evidence of prostate enlargement; by age 80, prevalence rises to nearly 90%. While BPH is not a malignancy, its progressive growth can compress the prostatic urethra and impair bladder function—triggering lower urinary tract symptoms (LUTS). Clinically, BPH-related LUTS evolve in stages: the initial irritative phase features urinary frequency, urgency, urge incontinence, and nocturia—often without overt obstructive signs. As the condition advances into the decompensated phase, patients develop obstructive symptoms including hesitancy, weak stream, straining, intermittent flow, incomplete emptying, and post-void dribbling. Importantly, nocturia frequently emerges before other symptoms become apparent—making it a critical early red flag for timely intervention.
A newly approved fixed-dose combination therapy—Aitinglie® (finasteride 5 mg/tadalafil 5 mg capsules)—offers a dual-pathway approach specifically designed for men with BPH-associated nocturia. Approved for the treatment of symptomatic BPH, this co-formulated agent simultaneously targets both the structural and functional drivers of LUTS.
Finasteride, a selective type II 5α-reductase inhibitor, reduces dihydrotestosterone (DHT) synthesis, thereby shrinking prostate volume over time—particularly beneficial in men with enlarged glands and moderate-to-severe LUTS. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, relaxes smooth muscle in the bladder neck, prostate capsule, and urethra, leading to rapid improvement in both storage-phase (e.g., nocturia, urgency) and voiding-phase (e.g., weak stream, straining) symptoms. Clinical evidence supports synergistic efficacy: combined PDE5 inhibition and 5α-reductase blockade improves IPSS scores, enhances quality-of-life metrics, and preserves erectile function more effectively than monotherapy alone.
Notably, Aitinglie® demonstrates a faster onset of symptom relief compared with finasteride monotherapy. While traditional 5α-reductase inhibitors typically require 3–6 months to achieve clinically meaningful reductions in prostate size and symptom burden, pivotal studies show measurable improvements in nocturia and overall IPSS within four weeks of initiating the combination regimen. Furthermore, the once-daily dosing simplifies adherence—reducing pill burden and minimizing missed doses, which is especially valuable in long-term management of a chronic condition like BPH.
In summary, for men whose nocturia stems from underlying BPH, Aitinglie® represents a mechanistically rational, evidence-informed therapeutic option. By concurrently addressing glandular enlargement and dynamic urethral resistance, it delivers both rapid symptomatic relief and sustained disease modification—offering a practical, patient-centered strategy to restore restorative sleep and preserve daily functioning.